Loading…
Pyronaridine: a review of its clinical pharmacology in the treatment of malaria
Abstract Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate...
Saved in:
Published in: | Journal of antimicrobial chemotherapy 2023-10, Vol.78 (10), p.2406-2418 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3 |
container_end_page | 2418 |
container_issue | 10 |
container_start_page | 2406 |
container_title | Journal of antimicrobial chemotherapy |
container_volume | 78 |
creator | Chu, Wan-Yu Dorlo, Thomas P C |
description | Abstract
Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria. |
doi_str_mv | 10.1093/jac/dkad260 |
format | article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_uu_512437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkad260</oup_id><sourcerecordid>2858405685</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3</originalsourceid><addsrcrecordid>eNp9kU9PGzEQxa2qqKShp34Bn6pKdGFsr_dPL1UUoCAhwQG4WhPvJDHdXaf2LijfHqNElXLpaQ7vN2-e5jH2VcCZgFqdP6M9b_5gIwv4wCYiLyCTUIuPbAIKdFbmWh2zzzE-A0Chi-oTO1Zloaqihgm7u98G32NwjevpJ0ce6MXRK_dL7obIbet6Z7HlmzWGDq1v_WrLXc-HNfEhEA4d9cM73WGbXPCEHS2xjfRlP6fs8eryYX6d3d79vpnPbjOby3LIZK4bVYEqraxETQg2xUS1qItSghVWQS2BZC51ri2qQiDBAq1WC7ISkj5lP3a-8ZU248JsguswbI1HZy7c08z4sDLjaLSQuSoT_muHJ7ajxqbQAduDrUOld2uz8i9GQEqgoUoO3_cOwf8dKQ6mc9FS22JPfoxGVrrKIb1XJ_R0h9rgYwy0_HdHgHmvzKTKzL6yRH_b0X7c_Bd8A3l7lpw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2858405685</pqid></control><display><type>article</type><title>Pyronaridine: a review of its clinical pharmacology in the treatment of malaria</title><source>Oxford Journals Online</source><creator>Chu, Wan-Yu ; Dorlo, Thomas P C</creator><creatorcontrib>Chu, Wan-Yu ; Dorlo, Thomas P C</creatorcontrib><description>Abstract
Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria.</description><identifier>ISSN: 0305-7453</identifier><identifier>ISSN: 1460-2091</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkad260</identifier><identifier>PMID: 37638690</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Editor's Choice ; Review</subject><ispartof>Journal of antimicrobial chemotherapy, 2023-10, Vol.78 (10), p.2406-2418</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3</citedby><cites>FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3</cites><orcidid>0000-0002-0402-8807</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512437$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, Wan-Yu</creatorcontrib><creatorcontrib>Dorlo, Thomas P C</creatorcontrib><title>Pyronaridine: a review of its clinical pharmacology in the treatment of malaria</title><title>Journal of antimicrobial chemotherapy</title><description>Abstract
Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria.</description><subject>Editor's Choice</subject><subject>Review</subject><issn>0305-7453</issn><issn>1460-2091</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kU9PGzEQxa2qqKShp34Bn6pKdGFsr_dPL1UUoCAhwQG4WhPvJDHdXaf2LijfHqNElXLpaQ7vN2-e5jH2VcCZgFqdP6M9b_5gIwv4wCYiLyCTUIuPbAIKdFbmWh2zzzE-A0Chi-oTO1Zloaqihgm7u98G32NwjevpJ0ce6MXRK_dL7obIbet6Z7HlmzWGDq1v_WrLXc-HNfEhEA4d9cM73WGbXPCEHS2xjfRlP6fs8eryYX6d3d79vpnPbjOby3LIZK4bVYEqraxETQg2xUS1qItSghVWQS2BZC51ri2qQiDBAq1WC7ISkj5lP3a-8ZU248JsguswbI1HZy7c08z4sDLjaLSQuSoT_muHJ7ajxqbQAduDrUOld2uz8i9GQEqgoUoO3_cOwf8dKQ6mc9FS22JPfoxGVrrKIb1XJ_R0h9rgYwy0_HdHgHmvzKTKzL6yRH_b0X7c_Bd8A3l7lpw</recordid><startdate>20231003</startdate><enddate>20231003</enddate><creator>Chu, Wan-Yu</creator><creator>Dorlo, Thomas P C</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-0402-8807</orcidid></search><sort><creationdate>20231003</creationdate><title>Pyronaridine: a review of its clinical pharmacology in the treatment of malaria</title><author>Chu, Wan-Yu ; Dorlo, Thomas P C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Editor's Choice</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, Wan-Yu</creatorcontrib><creatorcontrib>Dorlo, Thomas P C</creatorcontrib><collection>Open Access: Oxford University Press Open Journals</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, Wan-Yu</au><au>Dorlo, Thomas P C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pyronaridine: a review of its clinical pharmacology in the treatment of malaria</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><date>2023-10-03</date><risdate>2023</risdate><volume>78</volume><issue>10</issue><spage>2406</spage><epage>2418</epage><pages>2406-2418</pages><issn>0305-7453</issn><issn>1460-2091</issn><eissn>1460-2091</eissn><abstract>Abstract
Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37638690</pmid><doi>10.1093/jac/dkad260</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-0402-8807</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7453 |
ispartof | Journal of antimicrobial chemotherapy, 2023-10, Vol.78 (10), p.2406-2418 |
issn | 0305-7453 1460-2091 1460-2091 |
language | eng |
recordid | cdi_swepub_primary_oai_DiVA_org_uu_512437 |
source | Oxford Journals Online |
subjects | Editor's Choice Review |
title | Pyronaridine: a review of its clinical pharmacology in the treatment of malaria |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A19%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pyronaridine:%20a%20review%20of%20its%20clinical%20pharmacology%20in%20the%20treatment%20of%20malaria&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Chu,%20Wan-Yu&rft.date=2023-10-03&rft.volume=78&rft.issue=10&rft.spage=2406&rft.epage=2418&rft.pages=2406-2418&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkad260&rft_dat=%3Cproquest_swepu%3E2858405685%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c427t-245d38037c2819ea0c745a3b96720c1c30920e242545ca361ae0bac53bec201c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2858405685&rft_id=info:pmid/37638690&rft_oup_id=10.1093/jac/dkad260&rfr_iscdi=true |